^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    miR-101-5p overexpression

    i
    Other names: MIR101-1, MicroRNA 101-1, Hsa-MiR-101-5p, Hsa-MiR-101-3p, Hsa-Mir-101-1, MIRN101-1, Hsa-Mir-101-P1-V1, Hsa-Mir-101-P1-V2, MIMAT0004513, MIMAT0000099, Mir-101-1 , MI0000103, RF00253
    Entrez ID:
    406893
    almost4years
    miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. (PubMed, Breast Cancer (Dove Med Press))
    The ability of miR-101-5p to sensitize for treatment with lapatinib, tucatinib and trastuzumab was explored in HER2+ breast cancer cells responding poorly to such targeted drugs. miR-101-5p alone (p = 0.018) and in combination with lapatinib and trastuzumab (p < 0.001) induced apoptosis, while the targeted drugs alone did not exert any significant effect neither on proliferation nor apoptosis. miR-101-5p acts as a tumor suppressor by inducing apoptosis in HER2+ breast cancer and sensitizes cells with initially poor response to lapatinib and trastuzumab.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • miR-101-5p overexpression
    |
    Herceptin (trastuzumab) • lapatinib • Tukysa (tucatinib)